Ghafouri, Atieh
Jafari Karegar, Sahar
Hajiluian, Ghazaleh
Hosseini, Sharieh
Shidfar, Shahrzad
Kamalinejad, Mohammad
Hosseini, Agha Fatemeh
Heydari, Iraj
Shidfar, Farzad
Article History
Received: 29 August 2022
Accepted: 9 February 2023
First Online: 14 February 2023
Declarations
:
: Sixty patients with T2DM (male and female) were recruited in this double-blind, randomized, controlled clinical trial from the Institute of Endocrinology and Metabolism, Iran university of Medical Sciences, Tehran, Iran. All methods were performed in accordance with relevant guidelines and regulations of Helsinki declaration. The Ethical Committee of Iran University of Medical Sciences approved the study protocol, and was registered on the Iranian Registry of Clinical Trials website (http://www.irct.ir, identifier: IRCT201410142709N31, at the date of 11/12/2014). Written informed consent was received from all participants before clinical trial enrollment.
: Not applicable.
: The authors declare no competing interests.